Iovance Biotherapeutics (IOVA) 10-K 28 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 31, 2014	Jun. 30, 2013
Document And Entity Information	'	'	'
Entity Registrant Name	'Lion Biotechnologies, Inc.	'	'
Entity Central Index Key	'0001425205	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--12-31	'	'
Is Entity a Well-known Seasoned Issuer?	'No	'	'
Is Entity a Voluntary Filer?	'No	'	'
Is Entity's Reporting Status Current?	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$26,665,000
Entity Common Stock, Shares Outstanding	'	22,058,959	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2013	'	'

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current Assets	'	'
Cash and cash equivalents	$19,672,177	$0
Deposits	15,000	5,000
Prepaid expenses	158,716	2,275
Total current assets	19,845,893	7,275
Property and equipment, net of accumulated depreciation of $16,002 and $8,915	27,756	22,138
Total assets	19,873,649	29,413
Current Liabilities	'	'
Accounts payable	412,976	1,098,271
Accrued expenses	1,856,956	1,740,220
7% Senior secured convertible promissory notes	0	5,000,000
12% secured promissory notes	0	1,231,250
September 2012 secured promissory note	0	250,000
Accrued interest and penalty	0	2,029,148
Total Current Liabilities	2,269,932	11,348,889
Commitments and contingencies	'	'
Stockholders' Equity (Deficiency)	'	'
Preferred stock, $0.001 par value; 50,000,000 shares authorized, 17,000 shares and no shares issued and outstanding, respectively	17	'
Common stock, $0.000041666 par value; 18,000,000 shares authorized, 20,023,958 and 818,806 shares issued and outstanding, respectively	835	34
Common shares to be issued, 303,125 shares	245,153	245,153
Additional paid-in capital	81,884,897	19,119,532
Accumulated deficit	-64,527,185	-30,684,195
Total Stockholders' Equity (Deficiency)	17,603,717	-11,319,476
Total Liabilities and Stockholders' Equity (Deficiency)	$19,873,649	$29,413

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]	'	'
Property and equipment, accumulated depreciation	$16,002	$8,915
Stockholder's equity	'	'
Preferred Stock Par Value	$0.00	$0.00
Preferred Stock Authorized	50,000,000	50,000,000
Preferred Stock Issued	17,000	0
Preferred Stock Outstanding	17,000	0
Common Stock Par Value	$0.00	$0.00
Common Stock Shares Authorized	150,000,000	150,000,000
Common Stock Shares Issued	20,023,958	818,806
Common Stock Shares Outstanding	20,023,958	818,806
Common stock to be issued	303,125	0

Condensed_Statements_of_Operat

Condensed Statements of Operations (Unaudited) (USD $)	12 Months Ended		72 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Income Statement [Abstract]	'	'	'
Revenues	$0	$0	$0
Costs and expenses	'	'	'
Operating expenses (including $2,750,223, $2,528,254 and $10,138,952 of non-cash share-based compensation costs)	4,655,149	6,476,546	31,153,187
Cost of Lion transaction - related party	16,656,250	0	16,656,250
Research and development	1,329,367	1,656,000	4,912,412
Impairment of intangible asset	0	0	160,036
Total costs and expenses	22,640,766	8,132,546	52,881,885
Loss from operations	-22,640,766	-8,132,546	-52,881,885
Other income (expense)	'	'	'
Interest expense	-444,729	-1,922,063	-2,517,945
Change in fair value of derivative liabilities	0	8,635,147	10,001,955
Amortization of discount on convertible notes	0	-497,888	-5,497,888
Cost to induce exchange transaction	-2,295,868	0	-2,295,868
Financing costs	0	-1,390,269	-2,873,927
Total other income (expense)	-2,740,597	4,824,927	-3,183,673
Net Loss	-25,381,363	-3,307,619	-56,065,558
Deemed dividend related to beneficial conversion feature of convertible preferred stock	-8,461,627	0	-8,461,627
Net Loss Attributable to Common Stockholders	($33,842,990)	($3,307,619)	($64,527,185)
Net Loss Per Share Attributable to Common Stockholders, Basic and Diluted	($3.47)	($4.14)	'
Weighted-Average Common Shares Outstanding, Basic and Diluted	9,762,513	798,530	'

Condensed_Statements_of_Operat1

Condensed Statements of Operations (Parenthetical) (USD $)	12 Months Ended		72 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Costs and expenses	'	'	'
Share-Based Compensation	$2,750,223	$2,528,254	$10,138,952

Statements_of_Stockholders_Equ

Statements of Stockholders' Equity (Deficiency) (USD $)	Preferred Stock	Common Stock	Common Stock to Be Issued	Additional Paid-In Capital	Retained Earnings / Accumulated Deficit	Total
Beginning Balance Amount at Sep. 16, 2007	'	$5	'	$7,995	'	$8,000
Beginning Balance Shares at Sep. 16, 2007	'	126,600	'	'	'	'
Private placement, shares	'	254,400	'	'	'	'
Private placement, amount	'	11	'	52,989	'	53,000
Net loss	'	'	'	'	-58,716	-58,716
Ending Balance Amount at Dec. 31, 2008	'	16	'	60,984	-58,716	2,284
Ending Balance Shares at Dec. 31, 2008	'	381,000	'	'	'	'
Net loss	'	'	'	'	-15,772	-15,772
Ending Balance Amount at Dec. 31, 2009	'	16	'	60,984	-74,488	-13,488
Beginning Balance Shares at Dec. 31, 2009	'	381,000	'	'	'	'
Private placement, shares	'	145,783	'	'	'	'
Private placement, amount	'	6	0	1,909,994	0	1,910,000
Common stock issued for intellectual property, shares	'	209,600	'	'	'	'
Common stock issued for intellectual property, amount	'	9	'	217,399	'	217,408
Forgiveness of debt by director	'	'	'	18,137	'	18,137
Fair value of vested stock options and warrants	'	'	'	114,016	'	114,016
Net loss	'	'	'	'	-1,607,988	-1,607,988
Ending Balance Amount at Dec. 31, 2010	'	31	'	2,320,530	-1,682,476	638,085
Ending Balance Shares at Dec. 31, 2010	'	736,383	'	'	'	'
Common stock and warrant sold in private placement at $1.00 per share, April to June 2011, net of fair value of warrant derivative, shares	'	8,500	'	'	'	'
Common stock and warrant sold in private placement at $1.00 per share, April to June 2011, net of fair value of warrant derivative, amount	'	0	'	185,704	'	185,704
Common stock issued to consultants for services, Shares	'	4,602	'	'	'	'
Common stock issued to consultants for services, Amount	'	0	'	498,452	'	498,452
Cancellation of shares, Shares	'	-30,000	'	'	'	'
Cancellation of shares, Amount	'	-1	'	1	'	'
Fair value of common stock issued to officer for services, Shares	'	60,000	'	'	'	'
Fair value of common stock issued to officer for services, Amount	'	3	'	8,009,997	'	8,010,000
Fair value of vested stock options and warrants	'	'	'	1,793,904	'	1,793,904
Fair value of common stock transferred to officer	'	'	'	702,037	'	702,037
Fair value of common stock transferred from CEO to a director	'	'	'	1,040,000	'	1,040,000
Net loss	'	'	'	'	-25,694,100	-25,694,100
Ending Balance Amount at Dec. 31, 2011	'	33	'	14,595,625	-27,376,576	-12,780,918
Ending Balance Shares at Dec. 31, 2011	'	779,936	'	'	'	'
Private placement, shares	'	2,500	'	'	'	'
Private placement, amount	'	0	'	67,919	'	67,919
Forgiveness of debt by director	'	'	'	'	'	0
Fair value of common stock issued to consultatnt for services, Shares	'	15,495	'	'	'	'
Fair value of common stock issued to consultatnt for services, Amount	'	1	'	799,999	'	800,000
Fair value of common stock issued with notes payable recorded as a note discount, Shares	'	3,125	'	'	'	'
Fair value of common stock issued with notes payable recorded as a note discount, Amount	'	0	245,153	252,735	'	497,888
Fair value of common stock issued with notes payable recorded as financing cost, Shares	'	17,750	'	'	'	'
Fair value of common stock issued with notes payable recorded as financing cost, Amount	'	0	'	875,000	'	875,000
Fair value of vested stock options and warrants	'	'	'	2,528,254	'	2,528,254
Net loss	'	'	'	'	-3,307,619	-3,307,619
Ending Balance Amount at Dec. 31, 2012	'	34	245,153	19,119,532	-30,684,195	-11,319,476
Ending Balance Shares at Dec. 31, 2012	'	818,806	'	'	'	'
Private placement, shares	17,000	3,145,300	'	'	'	'
Private placement, amount	17	131	'	21,795,415	'	21,795,563
Common stock issued to induce exchange transaction, shares	'	2,173,134	'	'	'	'
Common stock issued to induce exchange transaction, amount	'	91	'	2,173,044	'	2,173,135
Common stock issued for cash under the restructuring, net of offering costs of $109,990, shares	'	1,350,000	'	'	'	'
Common stock issued for cash under the restructuring, net of offering costs of $109,990, amount	'	57	'	1,239,953	'	1,240,010
Forgiveness of debt by director	'	'	'	'	'	0
Common stock issued in settlement of notes payable and accrued interest and penalty, shares	'	9,267,641	'	'	'	'
Common stock issued in settlement of notes payable and accrued interest and penalty, amount	'	386	'	9,267,255	'	9,267,641
Fair value of common stock issued for cancellation of outstanding warrants, shares	'	122,734	'	'	'	'
Fair value of common stock issued for cancellation of outstanding warrants, amount	'	5	'	122,729	'	122,734
Common stock issued for Lion transaction, Shares	'	2,690,000	'	'	'	'
Common stock issued for Lion transaction, Amount	'	112	'	16,656,138	'	16,656,250
Common stock issued to directors, Shares	'	400,596	'	'	'	'
Common stock issued to directors, Amount	'	17	'	2,002,965	'	2,002,965
Common stock issued for settlement of payable, Shares	'	5,747	'	'	'	'
Common stock issued for settlement of payable, Amount	'	'	'	25,000	'	25,000
Common stock issued to consultants for services, Shares	'	50,000	'	'	'	'
Common stock issued to consultants for services, Amount	'	2	'	273,998	'	274,000
Fair value of vested stock options and warrants	'	'	'	747,241	'	747,241
Deemed dividend on beneficial conversion feature of preferred stock, amount	'	'	'	8,461,627	-8,461,627	'
Net loss	'	'	'	'	-25,381,363	-25,381,363
Ending Balance Amount at Dec. 31, 2013	$17	$835	$245,153	$81,884,897	($64,527,185)	$17,603,717
Ending Balance Shares at Dec. 31, 2013	17,000	20,023,958	'	'	'	'

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (Unaudited) (USD $)	12 Months Ended		72 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Cash Flows From Operating Activities	'	'	'
Net loss	($25,381,363)	($3,307,619)	($56,065,558)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation and amortization	7,087	6,211	77,373
Impairment of intangible asset	0	0	160,036
Fair value of vested stock options and warrants	747,241	2,528,254	5,183,415
Fair value of common stock and warrants accounted for as financing costs	0	0	2,986,819
Fair value of vested warrants granted for services	0	0	2,563,647
Amortization of discount on convertible notes	0	497,888	5,000,000
Private placement costs	0	515,273	385,000
Change in fair value of derivative liabilities	0	-8,635,147	-10,001,955
Common stock issued to officer for services	0	0	8,010,000
Common stock issued for services	274,000	800,000	1,572,452
Common stock issued to induce conversion of warrants	122,734	0	122,734
Common stock issued to induce exchange transaction	2,173,135	875,000	2,173,135
Common stock issued for Lion transaction	16,656,250	0	16,656,250
Common stock issued to directors	2,002,982	0	2,002,982
Fair value of common stock transferred to officer and director	0	0	1,742,037
Write off of advances to related party	0	0	50,000
Changes in assets and liabilities:	'	'	'
Deposits, prepaid expenses and other assets	-166,441	22,589	-173,716
Accounts payable, accrued expenses and interest and penalty	-543,560	2,580,547	2,294,932
Accrued interest and penalty	445,743	1,875,537	2,474,891
Net Cash Used In Operating Activities	-3,662,192	-2,241,467	-12,785,526
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'	'
Purchases of computer equipment	-12,705	0	-47,757
Advances to related party	0	0	-50,000
Net Cash Used In Investing Activities	-12,705	0	-97,757
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Proceeds from the issuance of convertible notes, net	311,500	0	4,926,500
Proceeds from the issuance of secured promissory notes, net	0	1,481,250	1,481,250
Proceeds from the issuance of common stock, net	7,126,813	250,000	10,220,813
Proceeds from the issuance of preferred stock, net	15,908,760	0	15,908,760
Due to director	0	0	18,137
Net Cash Provided By Financing Activities	23,347,073	1,731,250	32,555,460
Net Increase/(Decrease) In Cash And Cash Equivalents	19,672,177	-510,217	19,672,177
Cash and Cash Equivalents, Beginning of Period	0	510,217	0
Cash and Cash Equivalents, End of Period	19,672,177	0	19,672,177
Supplemental Disclosures of Cash Flow Information:	'	'	'
Derivative liability recorded upon issuance of convertible notes and warrants	0	0	5,535,310
Derivative liability recorded as offering cost	0	697,354	1,902,998
Common stock issued for intellectual property	0	0	217,408
Forgiveness of debt by director, treated as contribution of capital	0	0	18,137
Common stock issued upon conversion of convertible notes	6,792,750	0	6,792,750
Fair value of common stock issued with notes payable recorded as a note discount	0	497,888	497,888
Settlement of accounts payable through issuance of common stock	25,000	0	25,000
Common stock issued upon conversion of accrued interest and penalty	$2,474,891	$0	$2,474,891

1_GENERAL_ORGANIZATION_AND_BUS

1. GENERAL ORGANIZATION AND BUSINESS	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
NOTE 1. GENERAL ORGANIZATION AND BUSINESS	'
	Lion Biotechnologies, Inc. (the “Company,” “we,” “us” or “our”) was originally incorporated under the laws of the state of Nevada on September 17, 2007.  Until March 2010, we were an inactive company known as Freight Management Corp. On March 15, 2010, we changed our name to Genesis Biopharma, Inc., and in 2011 we commenced our current business.  On September 26, 2013, we amended and restated our Articles of Incorporation to, among other things, change our name to Lion Biotechnologies, Inc., effect a 1-for-100 reverse stock split (pro-rata reduction of outstanding shares) of our common stock, increase (after the reverse stock split) the number of our authorized number of shares of common stock to 150,000,000 shares, and authorize the issuance of 50,000,000 shares of “blank check” preferred stock, $0.001 par value per share.
	All common stock share and per share information contained in these financial statements has been adjusted to reflect the foregoing stock split as if it occurred at the earliest period presented.
	Lion Biotechnologies, Inc. is an emerging biotechnology company focused on developing and commercializing adoptive cell therapy (ACT) using autologous tumor infiltrating lymphocytes (TILs) for the treatment of metastatic melanoma and other solid cancers.  ACT utilizes T-cells harvested from a patient to treat cancer in that patient.  TILs, a kind of anti-tumor T-cells that are naturally present in a patient’s tumors, are collected from individual patient tumor samples. The TILs are then activated and expanded ex vivo and then infused back into the patient to fight their tumor cells.
	Development Stage
	We are currently in the development stage.  As a development stage company that is currently engaged in the development of therapeutics to fight cancer, we do not have any commercial products and have not yet generated any revenues from our biopharmaceutical business. We currently do not anticipate that we will generate any revenues during 2014 from the sale or licensing of any products. In addition, we have not generated any revenues from our prior business plans.
	Liquidity
	We have not had any revenues and are still in the development stage.  As shown in the accompanying financial statements, we have incurred a net loss of $25,381,000 for the year ended December 31, 2013 and used $3,662,000 of cash in our operating activities during the year ended December 31, 2013.  On November 5, 2013, in a private placement (the “Private Placement”), we issued and sold 3,145,300 shares of common stock, 17,000 shares of Series A Convertible Preferred Stock, and warrants to purchase 11,645,300 shares of common stock for an aggregate purchase price of $23,290,600 in cash.  The net proceeds of the Private Placement were approximately $21,985,000.  As a result of the foregoing financing, as of December 31, 2013, we had $19,672,000 of cash or cash equivalents on hand, stockholders’ equity of $17,604,000 and had working capital of $17,576,000.
	During 2014, we expect to further ramp up our operations, which will increase the amount of cash we will use in our operations.  Our budget for 2014 includes increased spending on research and development activities, higher payroll expenses as we increase our professional staff, as well as ongoing payments under the Cooperative Research and Development Agreement (CRADA) we have entered into with the National Cancer Institute (NCI).  Our budget anticipates that we will spend approximately $8 million to $10 million this year on budgeted expenditures, although that amount may change materially.  Based on the funds we had available on December 31, 2013, we believe that we have sufficient capital to fund our anticipated operating expenses for at least twelve months.
	Despite the amount of funds that we raised in the Private Placement, the estimated cost of completing the development of our TIL-based therapy, and of obtaining all required regulatory approvals to market those product candidates, is substantially greater than the amount of funds we had available on December 31, 2013.  Therefore, while we believe that our existing cash balances will be sufficient to fund our currently planned level of operations for at least twelve months, we will have to obtain additional funds in the future to complete our development plans.  We intend to seek this additional funding through various financing sources, including possible sales of our securities, and in the longer term through strategic alliances with other pharmaceutical or biopharmaceutical companies.

2_SUMMARY_OF_SIGNIFICANT_ACCOU

2. SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES	'
	Loss per Share
	Basic earnings (loss) per share is computed by dividing the net income (loss) applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed by dividing the net income (loss) applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. For the years ended December 31, 2013 and 2012, the calculations of basic and diluted loss per share are the same because inclusion of potential dilutive securities in the computation would have an anti-dilutive effect due to the net losses.
	The potentially dilutive securities at December 31, 2013 consist of options to acquire 278,750 shares of the Company’s common stock and warrants to acquire 12,373,156 shares of common stock.
	Fair Value Measurements
	The Company uses various inputs in determining the fair value of certain assets and liabilities and measures these on a recurring basis. Financial assets and liabilities recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. Authoritative guidance provided by the Financial Accounting Standards Board (the “FASB”) defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets and liabilities:
	Level 1—Quoted prices in active markets for identical assets or liabilities.
	Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.
	Level 3—Unobservable inputs based on the Company's assumptions.
	Derivative Financial Instruments
	The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives.  The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.  Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date.
	For stock-based derivative financial instruments, the Company used probability weighted average Black-Scholes-Merton models to value the derivative instruments at inception and on subsequent valuation dates through March 31, 2013.  At December 31, 2012, the Company used the assistance of a valuation specialist to determine the fair value of the derivative liability. On May 22, 2013, upon the completed restructuring of the Company’s debt and equity securities (“financial instruments”) (see Note 5), all financial instruments held at that time that were accounted for as a derivative liability were converted into shares of the Company’s common stock.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	Stock-Based Compensation
	The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for stock option and warrant grants issued and vesting to employees based on the authoritative guidance provided by the Financial Accounting Standards Board where the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board where the value of the stock compensation is determined based upon the measurement date as at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.
	The fair value of the Company's common stock option grants are estimated using a Black-Scholes option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.
	Recent Accounting Pronouncements
	The FASB has issued Accounting Standards Update (ASU) No. 2013-04, Liabilities (Topic 405), “Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date.” ASU 2013-04 provides guidance for the recognition, measurement, and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation within the scope of this ASU is fixed at the reporting date, except for obligations addressed within existing guidance in U.S. GAAP. The guidance requires an entity to measure those obligations as the sum of the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors and any additional amount the reporting entity expects to pay on behalf of its co-obligors. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company does not expect the adoption of this guidance to have a material impact on the Company’s financial statements.
	In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of Unrecognized Tax Benefit When a Net Operating Loss Carryforward, A Similar Tax Loss, or a Tax Credit Carryforward Exists (A Consensus the FASB Emerging Issues Task Force). ASU 2013-11 provides guidance on financial statement presentation of unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The FASB’s objective in issuing this ASU is to eliminate diversity in practice resulting from a lack of guidance on this topic in current U.S. GAAP. This ASU applies to all entities with unrecognized tax benefits that also have tax loss or tax credit carryforwards in the same tax jurisdiction as of the reporting date. This amendment is effective for public entities for fiscal years beginning after December 15, 2013 and interim periods within those years. The company does not expect the adoption of this standard to have a material impact on the Company’s financial position and results of operations.
	Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC did not or are not believed by management to have a material impact on the Company's present or future financial statements.

3_RESTRUCTURING_OF_DEBT

3. RESTRUCTURING OF DEBT	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
3. RESTRUCTURING OF DEBT	'
	Effective May 22, 2013, the Company completed a restructuring of its unregistered debt and equity securities ( the “Restructuring”) resulting in the issuance of shares of common stock in exchange for (i) the cancellation of the 12% Secured Promissory Notes, (ii) 7% Senior Secured Notes, (iii) September 2012 Secured Promissory Notes, (iv) 18% Notes and certain other indebtedness, (v) and the receipt of $1.35 million from the sale of shares of common stock (the “Restructuring”).  To effect the Restructuring, the Company entered into an exchange agreement (the “Exchange Agreement”) and a stock purchase agreement (the “Stock Purchase Agreement”). The Exchange Agreement, Stock Purchase Agreement and the transactions contemplated thereby are described in further detail below.  The terms of the Restructuring were determined in negotiations between the Company and the creditors and investors party thereto, and were approved by the Board of Directors, including a majority of the disinterested directors. The securities issued pursuant the Restructuring are exempt from registration under Section 4(2) of the Securities Act of 1933 (the “Securities Act”) and Rule 506 of Regulation D because, among other reasons, all offerees are “accredited investors” under Section 2(15) of the Securities Act, all participants were existing security holders of the Company, and no general solicitation or public advertisement was conducted in connection with the Restructuring.  The terms of the Restructuring are as follows:
	Exchange Agreement
	Before the Exchange Agreement was entered into on May 22, 2013, the Company had outstanding promissory notes payable, and accrued interest and penalties thereon, in the aggregate amount of $9,267,641.  These obligations arose as follows:
	·	From April to July 2012, we entered into Note and Common Stock Subscription Agreement (the “Subscription Agreement”) with accredited investors (collectively, the “Purchasers”) in connection with the subscription by the Purchasers for certain Secured Promissory Notes (the “2012 Secured Notes”) and shares of our common stock.  The 2012 Secured Notes bore interest at 12% per annum and were originally due to mature on June 30, 2012. The note maturity date was amended several times but was in default as of December 31, 2012.  As of December 31, 2012, and on May 22, 2013, the principal balance of these outstanding notes was $1,231,250. In addition, approximately $149,000 of interest and penalties was due as of May 22, 2013.
	·	On July 27, 2011 the Company completed an offering of $5,000,000 of its senior secured convertible promissory notes (the “Senior Secured Notes”). The Senior Secured Notes bore an interest rate of 7% per annum, were originally scheduled to mature on November 30, 2011, and were convertible into shares of the Company’s common stock at a conversion price of $125.00 per share, subject to adjustment. The terms and maturity date of the Senior Secured Notes had been amended several times, but were in default as of December 31, 2012.  As of December 31, 2012, and on May 22, 2013, the principal balance of these outstanding notes was $5,000,000. In addition, approximately $2,282,000 of interest and penalties was due as of May 22, 2013.
	·	On September 12, 2012, the Company issued a promissory note amounting to $250,000.  As amended, the note was due on demand, bore interest at a rate of 12% per annum and was secured by the Company’s assets.  As of December 31, 2012, and on May 22, 2013, the principal balance of this outstanding note was $250,000. In addition, approximately $24,000 of interest and penalties was due as of May 22, 2013.
	·	In January and May, 2013, the Company issued four (4) eighteen (18%) percent convertible promissory notes in the aggregate amount of $311,500 (each an “18% Note”) that were due on demand. As of May 22, 2013, the balance of these outstanding notes was $311,500.  In addition, approximately $19,000 of interest and penalties was due as of May 22, 2013.
	Under the Exchange Agreement, these creditors of the Company converted all of the foregoing outstanding debt into 9,267,641 shares of Common Stock at a conversion price of $1.00 per share.
	This Exchange Agreement terminated all outstanding promissory notes and warrants originally issued with these notes, and any anti-dilution protection thereunder.  In addition, all creditors and placement agents provided a release of all claims against the Company with respect to all rights and ownership of the Debt and warrants, in consideration of the shares issued pursuant to this Exchange Agreement.
	Stock Purchase Agreement
	In addition to the exchange agreement, certain creditors entered into a Stock Purchase Agreement that resulted in the sale of 1,100,000 shares of common stock at a price of $1.00 per share.  Furthermore, certain creditors purchased an additional of 250,000 shares of Common Stock at a purchase price of $1.00 per share under the exchange agreement, resulting in aggregate subscription of 1,350,000 shares of common stock for proceeds to the Company of $1,240,010, net of legal fees of $109,990.
	In addition, any investor participating in and purchasing a minimum amount of Common Stock in the financing received, for no further consideration, the number of shares of Common Stock that such Investor would have received in debt or equity transactions if the price per share of Common Stock in prior transactions where they purchased stock or convertible notes would have been $1.00 per share (the “Repricing Issuance”).  As such, the Company issued 2,173,134 shares of common stock to these investors, and reflected the fair value of such shares of $2,173,134 (based on a value of a $1.00 per share) as cost to induce the exchange.
	In addition, certain creditors and certain placement agents associated with the Debt, together holding warrants to purchase 40,800 shares of capital stock of the Company, exchanged such warrants and received one share of Common Stock in exchange for each share of capital stock of the Company underlying the warrants. All Investors and other parties holding warrants to purchase 81,934 shares of capital stock of the Company exchanged such warrants and received one share of Common Stock in exchange for each share of capital stock of the Company underlying the warrants.  In the aggregate, warrants to acquire 122,734 shares of common stock were cancelled and exchanged for 122,734 shares of common stock, which were valued at $122,734 and reflected as a financing cost in the accompanying statement of operations.
	In the aggregate, the Stock Purchase Agreement resulted in the issuance of 3,645,868 shares of common stock.

4_EQUITY_RESTRUCTURING

4. EQUITY RESTRUCTURING	12 Months Ended
	Dec. 31, 2013
Restructuring and Related Activities [Abstract]	'
4. EQUITY RESTRUCTURING	'
	Pursuant to the Restructuring discussed in Note 4, the Company underwent a significant change in ownership of its shares.  Under the Restructuring, certain creditors, Investors, placement agents and consultants were issued approximately 94% of the Company’s outstanding voting equity interests, with Ayer Capital Partners Master Fund, L.P. together with certain of its affiliates (the “Ayer Funds”) and Bristol Investment Fund, Ltd., together with certain of its affiliates (“Bristol”), who owned approximately 41% and 29% respectively of the Company’s outstanding voting securities immediately after the Restructuring.  Prior to the Restructuring, control of the Company was widely disseminated among various stockholders, including the Investors.  No single shareholder currently holds more than 25.4% of the voting shares after the Restructuring.
	On May 20, 2013, Martin Schroeder resigned from the Board of Directors.  In connection with the Restructuring, on May 22, 2013, Anthony Cataldo, Michael Handelman and William Andrews resigned from our Board of Directors. Finally, on May 24, 2013, our stockholders removed Dr. L. Stephen Coles from the Board and elected Paul Kessler to serve as an additional director on the Board.  Mr. Kessler is a director of Bristol Investment Fund, Ltd. and a manager of Bristol Capital, LLC who, collectively, hold approximately 27.5% of our currently outstanding shares of common stock. Under the Restructuring, Bristol converted approximately $2.92 million in Debt (including accrued interest and penalties) into shares of Common Stock, invested $341,111 in the Financing, received a Repricing Issuance, and exchanged 45,325 warrants for shares of capital stock of the Company into shares of Common Stock, collectively resulting in the issuance of approximately 3,910,000 shares of Common Stock to Bristol.
	Agreement with Lion Biotechnologies, Inc. (Related Party)
	On July 24, 2013, we entered into an Agreement and Plan of Merger (the “Lion Agreement”) with Lion Biotechnologies, Inc. (“Lion”), a privately owned Delaware corporation, and Genesis Biopharma Sub, Inc., our newly formed Delaware subsidiary. Lion was a non-operating entity with no assets and liabilities, and their only account balances were the shares held by its two (2) owners.
	In the Lion Agreement, Lion’s stockholders received, in exchange for all of their issued and outstanding shares of common stock, an aggregate of 1,340,000 shares of our Common Stock with a fair value of $6,700,000. The acquisition was done to acquire access to technical and managerial resources to build our current and future products, which we believed would enhance or future operations and enable us to obtain additional funding. The technical resources that we acquired included access to next generation T-cell technologies (including term sheets for such technologies), access to cancer vaccine technologies that Lion was evaluating at Harvard University, NIH, Baylor University and other institutions, and other proprietary technologies and ideas on novel T-cell manufacturing technologies that Lion was designing. The value of these shares of $6,700,000 was recognized and recorded as an expense during the year ended December 31, 2013.
	In addition, the Lion stockholders had the ability to receive an additional 1,350,000 shares of Common Stock upon the achievement of two milestones related to the Company’s financial performance and position.  In November and December 2013 both of the milestones were met and, accordingly, the Company was required to issue the remaining 1,350,000 shares of Common Stock to the Lion Biotechnologies’ former stockholders.  These additional shares were issued in the fourth quarter of 2013, and the Company determined their fair value on the dates of issuance to be $9,956,250 in the aggregate, based on the trading prices of the Company’s stock at the date of achievement of the two milestones.  The aggregate fair value of all shares issued under the Lion transaction of $16,656,250 was  recognized and recorded as Cost of Lion transaction on the Company’s accompanying statement of operations for the year ended December 31, 2013.
	As part of the Lion transaction, Dr. Manish Singh entered into an employment agreement with us whereby we appointed him as our Chief Executive Officer and Chairman of the Board of the Company.  We also agreed to reconstitute our Board of Directors, which changes became effective on September 3, 2013.  In connection with his appointment as Chief Executive Officer and Chairman of the Board, we entered into an employment agreement with Dr. Singh pursuant to which we were required to pay Dr. Singh an annual base salary of $34,000 until this Company raised at least $1,000,000 in additional financing.  Effective November 6, 2013, upon the closing of a Private Placement with proceeds of $23.3 million to the Company (see Note 5), Dr. Singh’s annual salary increased to $350,000.  In addition to his base salary, Dr. Singh will be eligible to participate in the Company’s annual incentive compensation program, with a target potential bonus of 30% of Dr. Singh’s salary, conditioned upon the satisfaction of individual and company objectives.  Dr. Singh is also entitled to health and other benefits programs and, on July 24, 2014, he will become eligible to receive stock option grants under the Company’s stock option plan.
	On February 5, 2014, the Compensation Committee awarded Dr. Manish Singh, the Company’s Chief Executive Officer, a cash bonus of $100,000 under his Employment Agreement for his services rendered in 2013, which was included in accrued expenses in the accompanying balance sheet as of the year ended December 31, 2013.
	Amended and Restated Articles
	Effective September 26, 2013, the Company amended and restated its articles of incorporation.  The Amended and Restated Articles of Incorporation effected the following:
	(1) a 1-for-100 reverse stock split (pro-rata reduction of outstanding shares) of Common Stock (the “Reverse Stock Split”).  All share and per share amounts included in these financial statements have been retroactively restated to reflect the reverse stock split as if it had occurred at the beginning of the earliest period presented.
	(2) to fix the number of authorized shares of Common Stock after the Reverse Stock Split at one hundred and fifty million (150,000,000) shares of Common Stock, which change resulted in an increase in the authorized number of shares of Common Stock.
	(3) to authorize the issuance of fifty million (50,000,000) shares of “blank check” preferred stock, $0.001 par value per share, to be issued in series, and all properties of such preferred stock to be determined by the Company’s Board.
	(4) to change the name of the Company to “Lion Biotechnologies, Inc.”
	(5) to add indemnification and limit the personal liability of officers and members of the Company’s Board of Directors.
	Amendment to 2011 Plan
	The Company’s Board of Directors and the holders of a majority of the issued and outstanding shares of common stock approved an amendment to the Company’s 2011 Equity Incentive Plan (the “2011 Plan”) (a) to increase the number of shares of common stock authorized for issuance under the 2011 Plan from 180,000 shares of common stock to 1,700,000 shares of common stock, (b) increasing the maximum number of shares eligible for issuance under the 2011 Plan in any twelve-month period from 50,000 shares of common stock to 300,000 shares of common stock.
	Director Stock Awards
	On July 24, 2013, the Company entered into a Director Stock Award Agreement (the “Award Agreement”) with each of General Merrill McPeak, Matrix Group International, Inc. (on behalf of David Voyticky) (“Matrix”) and Bristol Capital, LLC (on behalf of Paul Kessler) (“Bristol”) whereby General McPeak, Matrix and Bristol each received 133,532 shares of Common Stock or an aggregate of 400,596 shares with a fair value of $2,002,982 for consideration of services rendered as directors.  The terms of the Award Agreement were approved by a majority of the Company’s stockholders, including a majority of the disinterested stockholders.  The securities issued pursuant the Award Agreement are exempt from registration under Section 4(2) of the Securities Act of 1933 (the “Securities Act”) because, among other reasons, all offerees are “accredited investors” under Section 2(15) of the Securities Act and no general solicitation or public advertisement was conducted in connection with the issuance.

5_DERIVATIVE_LIABILITIES

5. DERIVATIVE LIABILITIES	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
NOTE 5. DERIVATIVE LIABILITIES	'
	In June 2008, the FASB issued authoritative guidance on determining whether an instrument (or embedded feature) is indexed to an entity’s own stock.  Under the authoritative guidance, effective January 1, 2009, instruments which did not have fixed settlement provisions were deemed to be derivative instruments.  The convertible notes and warrants issued related prior to 2012 did not have fixed settlement provisions because their conversion and exercise prices may be lowered if the Company issues securities at lower prices in the future.  The conversion feature and warrants have been characterized as derivative liabilities to be re-measured at the end of every reporting period with the change in value reported in the statement of operations.  The value of these derivatives was determined to be $7,737,793 as of December 31, 2011.  During the period through September 30, 2012, the Company issued additional convertible notes and warrants that did not have fixed settlement provisions for which the Company determined the value of the derivative liabilities increased by $897,354 to $8,635,147. The Company used a probability weighted average Black-Scholes-Merton model to value these derivative instruments.
	The Company used the assistance of a valuation specialist to determine the fair value of its derivative liability at December 31, 2012.  As a result of the Company’s inability to pay its debt obligations, the default status of its convertible promissory notes and lack of available working capital at December 31, 2012, for valuation purposes, the Company, with the assistance of the independent valuation expert, determined that the effect of the default and insolvent financial condition, as such, was that the outstanding conversion features and warrants accounted for as derivative upon their issuance had no more value at December 31, 2012. For the year ended December 31, 2012, the Company recorded a gain due to the decrease in fair value of the derivative liabilities of $8,635,147.
	On May 22, 2013, upon the completed restructuring of the Company’s debt and equity securities (“financial instruments”) (see Note 3), all financial instruments held at that time that were subjected to derivative accounting were converted into shares of the Company’s common stock, thereby eliminating all applicable derivative liabilities.

6_PRIVATE_PLACEMENT

6. PRIVATE PLACEMENT	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
6. PRIVATE PLACEMENT	'
	On October 30, 2013, the Company, entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with the institutional and other accredited investors identified therein (each, an “Investor” and collectively, the “Investors”), relating to a private placement (the “Private Placement”) through the sale of the Company’s Common stock, Series A Convertible Preferred Stock ("Preferred stock"), and Warrants to Purchase Common Stock (“Warrants”) for an aggregate gross proceeds of $23,290,600.  Under the Securities Purchase Agreement, the Investors agreed to purchase units consisting of either (i) 3,145,300 shares of Common Stock, and Warrants to purchase an aggregate of 3,145,300 shares of Common stock at a purchase price of $2.00 per unit resulting in gross proceeds of $6,290,600; or (ii) 17,000 shares of Series A Convertible Preferred Stock, and Warrants to purchase 8,500,000 shares of Common Stock at a purchase price of $1,000 per unit, resulting in gross proceeds to the Company of $17,000,000.
	In connection with the Placement, the Company incurred $1,495,037 of direct offering costs, resulting in net proceeds to the Company of 21,795,563. In addition, the Company granted warrants to purchase an aggregate of 726,856 shares of the Company’s common stock to the placement agents.
	The Warrants are exercisable in whole or in part, at an initial exercise price per share of $2.50, and may be exercised in a cashless exercise if, after six months, there is no effective Registration Statement registering, or no current prospectus available for, the resale of the Warrant shares.  The exercise price and number of shares of Common Stock issuable under the Warrants are subject to adjustments for stock dividends, splits, combinations and similar events. The Warrants may be exercised at any time upon the election of the holder, beginning on the date of issuance and ending on the fifth anniversary of the date of issuance.
	Series A Convertible Preferred Stock
	A total of 17,000 shares of Series A Convertible Preferred Stock (the “Series A Preferred Stock”) have been authorized for issuance under the Certificate Of Designation Of Preferences And Rights Of Series A Convertible Preferred Stock (the “Certificate of Designation”).  The shares of Series A Preferred Stock have a stated value of $1,000 per share and are initially convertible into shares of Common Stock at a price of $2.00 per share (subject to adjustment as described below).  Under the Certificate of Designation, the holders of the Series A Preferred Stock have the following rights, preferences and privileges:
	The Series A Preferred Stock may, at the option of the Investor, be converted at any time or from time to time into fully paid and non-assessable shares of Common Stock at the conversion price in effect at the time of conversion; provided, that a holder of Series A Preferred Stock may at any given time convert only up to that number of shares of Series A Preferred Stock so that, upon conversion, the aggregate beneficial ownership of the Company’s Common Stock (calculated pursuant to Rule 13d-3 of the Securities Exchange Act of 1934, as amended) of such Investor and all persons affiliated with such Investor, is not more than 4.99% of the Company’s Common Stock then outstanding (subject to adjustment up to 9.99% solely at the Investor’s discretion upon 60 days’ prior notice).  The number of shares into which one share of Series A Preferred Stock shall be convertible is determined by dividing the stated value of $1,000 per share by the initial Conversion Price.  The "Conversion Price" per share for the Series A Preferred Stock is initially equal to $2.00 (subject to appropriate adjustment for certain events, including stock splits, stock dividends, combinations, recapitalizations or other recapitalizations affecting the Series A Preferred Stock).
	The Series A Preferred Stock will automatically be converted into Common Stock at the then applicable Conversion Price (i) upon the written consent of the Investors holding at least a majority of the outstanding shares of Series A Preferred Stock or (ii) if required by the Company for the Company to list its Common Stock on a national securities exchange; provided, any such conversions will continue to be limited by, and subject to the beneficial ownership conversion limitations set forth above.
	Except as otherwise required by law, the holders of shares of Series A Preferred Stock shall not have the right to vote on matters that come before the stockholders; provided, that the Company will not, without the prior written consent of a majority of the outstanding Series A Preferred Stock: (i) amend, alter, or repeal any provision of the Articles of Incorporation (including the Certificate of Designation setting forth the rights of the Series A Preferred Stock) or Bylaws in a manner adverse to the Series A Preferred Stock; (ii) create or authorize the creation of or issue any other security convertible into or exercisable for any equity security, having rights, preferences or privileges senior to or on parity with the Series A Preferred Stock, or increase the authorized number of shares of Series A Preferred Stock; (iii) issue or sell any equity or debt securities for one year after the initial sale of the Series A Preferred Stock, subject to certain specified and other customary exceptions; or (iv) enter into any agreement with respect to any of the foregoing.
	In the event of any dissolution or winding up of the Company, whether voluntary or involuntary, the proceeds shall be paid pari passu among the holders of the shares of Common Stock and Preferred Stock, pro rata based on the number of shares held by each such holder, treating for this purpose all such securities as if they had been converted to Common Stock.
	The Company may not declare, pay or set aside any dividends on shares of any class or series of capital stock of the Company (other than dividends on shares of Common Stock payable in shares of Common Stock) unless the holders of the Series A Preferred Stock shall first receive, or simultaneously receive, an equal dividend on each outstanding share of Series A Preferred Stock.
	The Company analyzed the conversion feature associated with the Series A Preferred for derivative accounting under ASC 815-20 and ASC 815-15, and determined that the conversion feature met the criteria for classification in equity and did not require derivative treatment under ASC 815-20 and ASC 815-15.
	In accordance with ASC 470-20, the Company determined that the common stock into which the Series A Preferred on the date of issuance of the Series A Preferred was convertible at less than the fair value of the common shares using the relative fair method, resulting in a beneficial conversion feature that the Company recognized as an increase to additional paid-in capital and a deemed dividend to the Series A Preferred stockholders of $8,461,627.
	Registration Rights Agreement.
	The Company also entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the Investors, which sets forth the rights of the Investors to have their shares of Common Stock purchased in the Private Placement and the shares of Common Stock issuable upon (i) the conversion of the Series A Preferred Stock and (ii) the exercise of the Warrants, registered with the Securities and Exchange Commission (the “SEC”) for public resale under the Securities Act.  The Company will also be required to maintain the effectiveness of the Registration Statement until the earlier to occur of (i) the date on which all of the registrable securities covered by the Registration Rights Agreement have been sold; or (ii) transferred in a manner that they may be resold without subsequent registration under the Securities Act. The registration agreement was filed in December 2013 and was declared effective by the Securities and Exchange Commission on January 30, 2014.

7_STOCKHOLDERS_EQUITY_DEFICIEN

7. STOCKHOLDERS EQUITY (DEFICIENCY)	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
7. STOCKHOLDERS EQUITY (DEFICIENCY)	'
	Year ended December 31, 2013
	On October 31, 2013, the Company granted 50,000 shares of common stock for consulting services. These shares were valued at $274,000 based on the trading price of the Company’s common stock at the date of the agreement.
	On November 18, 2013, the Company granted 75,000 shares of restricted stock to a new employee and 25,000 shares to a second new employee.  The foregoing 100,000 shares of restricted stock vest over three years.  Any unvested shares are forfeited and returned to the Company if the employees cease to being employed before the shares are fully vested.  As no shares vested during the year ended December 31, 2013, no compensation expense was recognized on these 100,000 shares of restricted stock granted during the year then ended.
	On November 14, 2013, the Company also issued 5,747 shares of common stock to a creditor as payment for outstanding obligations.  The fair value of the 5,747 shares issued was $25,000 based on the trading price of the Company’s common stock at the date of settlement of the obligation, which was reduced by the total fair value of the shares issued of $25,000.
	Year ended December 31, 2012
	Issuance of common stock and warrants for cash
	In February 2012, the Company sold 2,500 shares of its common stock and a five-year warrant to purchase 2,500 shares for $250,000. The warrant agreement included an anti-dilution provision that allowed for the automatic reset of the number of warrants issued and exercise price of the warrants upon any future sale of common stock or warrants at or below the current exercise price.  As a result, the Company determined that these warrants are not considered indexed to the Company’s own stock and characterized the fair value of these warrants as an offering cost and derivative liabilities upon issuance.  The aggregate value of these warrants issued was $182,081 using the probability weighted average Black-Scholes-Merton option valuation model.
	Issuance of common stock for services
	In January 2012, the Company issued 15,495 shares of common stock with a fair value of $800,000 for services.  The shares of common stock issued were valued at the market price on the date of issuance.
	In July 2012, Company issued 15,000 shares of common stock with a fair value of $750,000 to the principal of a firm engaged to seek financing and other strategic relationships for the Company. The shares of common stock issued were valued at the market price on the date of issuance.
	Issuance of common stock with Promissory Notes
	From April to July 2012, the Company agreed to issue 6,156 shares of its common stock with a fair value of $497,888 to the Purchasers of its promissory notes.  Subsequently, a total of 3,125 shares of common stock were issued during the year ended December 31, 2012 and 3,031 shares of common stock valued at $245,133 remains to be issued as of December 31, 2013.  The shares of common stock issued were valued at the market price on the date of grant and recorded as a debt discount that was amortized to interest expense.
	In September 2012, the Company issued an aggregate of 17,750 shares of common stock with a fair value of $875,000 to a holder of the Company’s promissory note.  The shares of common stock issued were valued at the market price on the date of issuance and recorded as a financing cost.

8_STOCK_OPTIONS_AND_WARRANTS

8. STOCK OPTIONS AND WARRANTS	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
8. STOCK OPTIONS AND WARRANTS	'
	Stock Options
	As of October 14, 2011, the Company’s Board of Directors, based upon the approval and recommendation of the Compensation Committee, approved by unanimous written consent the Company’s 2011 Equity Incentive Plan (the “2011 Plan”) and form of option agreements for grants under the 2011 Plan.  Employees, directors, consultants and advisors of the Company are eligible to participate in the 2011 Plan.  The 2011 Plan will be administered by the Board of Directors or the Company’s Compensation Committee and has 1,700,000 shares of common stock reserved for issuance in the form of incentive stock options (available for issuance to employees, and only upon shareholder approval of the 2011 Plan); non-qualified options; common stock; and grant appreciation rights. No person eligible to participate in the 2011 Plan shall be granted options or other awards during a twelve month period that exceeds 300,000 shares. No options or stock appreciation rights may be granted after ten years of the adoption of the 2011 Plan by the Board of Directors, nor may any option have a term of more than ten years from the date of grant. The exercise price of non qualified options and the base value of a stock appreciation right shall not be less than the fair market value of the common stock on the date of grant. The exercise price of an incentive stock option shall not be less than the fair market value of the stock covered by the option at the time of grant and in instances where a grantee possesses more than 10% percent of the combined voting power of all classes of stock of the Company, the exercise price shall not be less than 110% percent of the fair market value of the common stock at the time of grant.  The Company’s stockholders did not approve the 2011 Plan within the required one-year period.  Accordingly, the Company cannot grant incentive stock options under the 2011 Plan.
	A summary of the status of stock options at December 31, 2013 and 2012 is presented in the following table:
								Weighted
					Weighted			Average
		Shares			Average			Remaining	Aggregate
		Under			Exercise			Contractual	Intrinsic
		Option			Price			Life	Value
	Outstanding at December 31, 2011		92,750		$	109		8.5 years	$	1,114,063
	Granted		3,000			104
	Exercised
	Expired/Forfeited		(2,000	)		92
	Outstanding at December 31, 2012		93,750			107		7.7 years	$	217,063
	Granted		225,000			5.65
	Exercised
	Expired/Forfeited		(40,000	)		125
	Outstanding at December 31, 2013		278,750		$	23.1		9.1 years	$	1,176,063
	Exercisable at December 31, 2013		81,687		$	45.1		7.8 years	$	344,642
	On August 31, 2013, 25,000 options to purchase common stock granted to Mr. Cataldo with unamortized compensation cost of $1,611,698 were forfeited as a result of his resignation as our chief executive officer effective June 1, 2013. See Note 10.
	On March 1, 2011, the Company entered into an employment agreement that provided for the grant of options to purchase 25,000 shares of its common stock at an exercise price of $125.00.  The options were to vest as follows: a) 5,000 shares vested immediately and b) 20,000 shares vest in equal monthly installments over the two-year term of the agreement. Neither the Board of Directors nor the Compensation Committee approved the grant of the foregoing options. Accordingly, the Company may be obligated to grant these options, but has not done so yet. Therefore, as the grant of these options has not been approved, they are not included in compensation expense or in number of granted options listed as of and for the years ended December 31, 2013 and 2012.
	On November 18, 2013, each non-executive director of the Company was granted an option to purchase up to 40,000 shares at an exercise price of $5.65 per share (the closing price of our common stock on the date of grant). Options for 10,000 of these shares vested upon grant, with the remaining options vesting over the next three quarterly periods. These options have a ten-year term and will be exercisable for two years following termination of service as a member of our Board of Directors, unless the Director is terminated for cause, in which case the options will be terminated. The aggregate fair value of these options at the date of grant was determined to be $674,071 based on the Black-Scholes-Merton option pricing model.
	During 2013, the Company granted to employees options to purchase 100,000 shares of its common stock at an exercise price of $5.65. None of these options vested immediately, and the remaining 100,000 options begin vesting on the one year anniversary in equal monthly installments quarterly over the remaining terms of the agreements. During 2013, the Company also granted to a consultant options to purchase 5,000 shares of its common stock at an exercise price of $5.65, and which vested immediately.
	The aggregate fair values of the options granted in 2013 and 2012 were $1,265,094 and $146,443, respectively. The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model that uses the assumptions noted in the following table. For purposes of determining the expected life of the option, an average of the estimated holding period is used. The risk-free rate for periods within the contractual life of the options is based on the U. S. Treasury yield in effect at the time of the grant.
		Year ended
		December 31,
		2013			2012
	Expected volatility		236	%		208	%
	Expected dividends		0			0
	Expected average term (in years)		5.38			4.25
	Risk free rate - average		2.67	%		1.78	%
	Forfeiture rate		0			0
	During the years ended December 31, 2013 and 2012, the Company recorded compensation costs of $747,241 and $2,528,254, respectively, relating to the vesting of the stock options discussed above.  As of December 31, 2013, the aggregate value of unvested options was $1,101,224, which will continue to be amortized as compensation cost as the options vest over terms ranging from 9 months to 5 years, as applicable.
	Warrants
	A summary of the status of stock warrants at December 31, 2013 and 2012 is presented in the following table:
								Weighted
					Weighted			Average
		Shares			Average			Remaining	Aggregate
		Under			Exercise			Contractual	Intrinsic
		Warrants			Price			Life	Value
	Outstanding at December 31, 2011		96,800		$	122		4.5 years	$	-
	Issued		11,934			125
	Exercised
	Expired		-
	Outstanding at December 31, 2012		108,734		$	123		3.5 years	$	-
	Issued		12,387,156			2.5
	Exercised		-122,734
	Expired		-
	Outstanding and exercisable at December 31, 2013		12,373,156		$	2.51		4.11 years	$	31,056,390
	The Company, in connection with the November 2013 offering, issued warrants to purchase an aggregate of 11,645,300 shares of its common stock to investors, and warrants to purchase an aggregate of 726,856 shares of its common stock to placement agents, in connection with the sale of its securities for cash under the Private Placement (see Note 6).  All of these warrant grants have an exercise price per share of $2.50, are fully vested, and will expire in 2018.

9_INCOME_TAXES

9. INCOME TAXES	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
9. INCOME TAXES	'
	The Company has no tax provision for any period presented due to our history of operating losses. As of December 31, 2013, the Company had net operating loss carry forwards of approximately $10,636,151 that may be available to reduce future years' taxable income through 2033. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as management has determined that their realization is not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards.
	Significant components of the Company’s deferred income tax assets are as follows as of:
		December 31,			December 31,
		2013			2012
	Deferred income tax asset:
	Net operating loss carry forward		3,679,022			6,957,129
	Valuation allowance		(3,679,022	)		(6,957,129	)
	Net deferred income tax asset	$	—		$	—
	Reconciliation of the effective income tax rate to the U.S. statutory rate is as follows:
		Year Ended
		December 31,
		2013			2012
	Federal Statutory tax rate		(34	) %		(34	) %
	State tax, net of federal benefit		(5	) %		(5	) %
			(39	) %		(39	) %
	Valuation allowance		39	%		39	%
	Effective tax rate		-	%		-	%
	The Company adopted accounting rules which address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under these rules, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. These accounting rules also provide guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. As of December 31, 2013, no liability for unrecognized tax benefits was required to be recorded.

10_LICENSE_AND_COMMITMENTS

10. LICENSE AND COMMITMENTS	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
NOTE 7. LICENSE AND COMMITMENTS	'
	National Institutes of Health and the National Cancer Institute
	Effective August 5, 2011, the Company signed a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health and the National Cancer Institute (NCI). Under the terms of the five-year cooperative research and development agreement, the Company will work with Steven A. Rosenberg, M.D., Ph.D., chief of NCI’s Surgery Branch, to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient’s tumor infiltrating lymphocytes.
	The Company will provide funds in the amount of $1,000,000 per year of the CRADA for Dr. Rosenberg to use to acquire technical, statistical, and administrative support for the research activities, as well as to pay for supplies and travel expenses.  The Company will provide funds in the amount of $250,000 on a quarterly basis.  The first quarterly installment of $250,000 was due within thirty (30) days of the Effective Date of the CRADA and each subsequent installment will be due within thirty (30) days of each quarterly anniversary of the December 5, 2011 Effective Date.  In addition, although the CRADA has a five year term, either party to the CRADA has the right to terminate the CRADA upon 60 days’ notice to the other party.
	For each of the years ended December 31, 2013 and 2012, the Company recognized $1,000,000 of CRADA expenses, which were recorded as part of research and development expenses in the statement of operations during the years then ended.  As of December 31, 2013 and 2012, $250,000 and $500,000, respectively, was due under these agreements.
	National Institutes of Health
	Effective October 5, 2011, the Company entered into a Patent License Agreement (the “License Agreement”) with the National Institutes of Health, an agency of the United States Public Health Service within the Department of Health and Human Services (“NIH”).  Pursuant to the License Agreement, NIH granted to the Company a non-exclusive worldwide right and license to develop and manufacture certain proprietary autologous tumor infiltrating lymphocyte adoptive cell therapy products for the treatment of metastatic melanoma, ovarian cancer, breast cancer, and colorectal cancer.  The license agreement required us to pay the NIH approximately $723,000 of upfront licensing fees and expense reimbursements in 2011, which amounts were included in Research and Development expenses in fiscal 2011.  In addition, the Company will have to pay royalties of six percent (6%) of net sales (subject to certain annual minimum royalty payments), a percentage of revenues from sublicensing arrangements, and lump sum benchmark royalty payments on the achievement of certain clinical and regulatory milestones for each of the various indications and other direct cost incurred by NIH pursuant to the agreement.  The Company initially intends to focus on the development of licensed products in the metastatic melanoma field of use.  If the Company achieves all benchmarks for metastatic melanoma, up to and including the product’s first commercial sale in the United States, the total amount of such benchmark payments will be $6,050,000.  The benchmark payments for the other three indications, if all benchmarks are achieved, will be $6,050,000 for ovarian cancer, $12,100,000 for breast cancer, and $12,100,000 for colorectal cancer.  Accordingly, if the Company achieves all benchmarks for all four licensed indications, the aggregate amount of benchmark royalty payments that the Company will have to make to NIH will be $36,300,000.
	During the years ended December 31, 2013 and 2012, there were no net sales subject to certain annual minimum royalty payments, a percentage of revenues from sublicensing arrangements.  In addition there were no benchmarks or milestones achieved that would require payment under the lump sum benchmark royalty payments on the achievement of certain clinical and regulatory milestones for each of the various indications.
	During the years ended December 31, 2013 and 2012, the Company recognized $329,367 and $636,000, respectively, of NIH expenses, which were recorded as part of research and development expenses in the accompanying statements of operations during the years then ended.  As of December 31, 2013 and 2012, $941,659 and $682,292, respectively were due under the License Agreement with NIH.  On January 17, 2014, the Company paid the NIH the entire past due amount of $941,659 payable to the NIH under the License Agreement, and the Company is now current with all of its payment obligations under the License Agreement.

11_RELATED_PARTY_TRANSACTIONS

11. RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
NOTE 11. RELATED PARTY TRANSACTIONS	'
	Accrued Payroll and Fees
	As of December 31, 2013 and 2012, the Company accrued the unpaid salaries of its officers and fees due to members of the Company’s board of directors in the amount of $338,731 and $395,081 respectively, which is included in accrued expenses in the accompanying balance sheet.
	Settlement with Mr. Cataldo
	On June 19, 2013, the Company entered into a Settlement Agreement and General Release of All Claims (the “Settlement Agreement”) with Anthony Cataldo, this Company’s former Chief Executive Officer.  Under the Settlement Agreement, the Company agreed to pay Mr. Cataldo a cash payment of $370,000 when the Company obtains financing of more than $5,000,000.  The $370,000 was to be paid as follows: (a) a payment of $120,000, less all appropriate federal and state income and employment taxes, would be paid in cash, and (b) and another payment of $250,000, less all appropriate federal and state income and employment taxes, would be paid in the same securities as sold in the next financing.  On November 5, 2013, the Company completed a financing of more than $5,000,000 and, as a result, the foregoing $370,000 payment became due and payable.  On November 18, 2013, the Company and Mr. Cataldo agreed to revise the terms of the Settlement Agreement and to reduce the foregoing $370,000 payment to $250,000, payable in cash as payment in full for all amounts owed to him under the Settlement Agreement.  The $250,000 payment has been made as of the year ended December 31, 2013.
	Emmes Group Consulting LLC
	Effective as of February 15, 2011, the Company entered into a consulting agreement with Emmes Group Consulting LLC, a strategic business consulting firm (“Emmes”). Mr. Schroeder, a former director of the Company, is an Executive Vice President and Managing Director of Emmes and the Emmes Group, Inc. Under the consulting agreement, Emmes agreed to assist and advise us with respect to the development of an overall strategic business plan, the identification of in-licensing therapeutic opportunities, and raising debt and equity capital. In consideration for the foregoing consulting services, we issued to Emmes a ten-year warrant to purchase up to 1,000 shares of our common stock at an exercise price of $126.00 per share. In addition, we agreed to pay Emmes $10,000 per month. The initial term of the consulting agreement expired on May 15, 2011, but continued in accordance with the terms of the consulting agreement for an unspecified term until terminated at any time by either party with or without cause. Effective August 1, 2011, the Company amended the consulting agreement to increase the monthly consulting fee to $20,000, commencing as of July 11, 2011. The amendment also extended the term of the consulting agreement to December 31, 2011.
	On February 12, 2012, the Company entered into a Second Amendment to the Consulting Agreement, engaging the Emmes Group as its senior contractor and project manager responsible for the overall management of the design, development, implementation, and installation of our corporate and regulatory compliant information technology infrastructure and systems. The consulting agreement with Emmes Group was terminated in January 2013.
	During the year ended December 31, 2013, the Company recognized a total of $22,412 of consulting expenses from Emmes, which was recorded as part of operating expenses in the statement of operations.

2_SUMMARY_OF_SIGNIFICANT_ACCOU1

2. SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Policies)	12 Months Ended
	Dec. 31, 2013
Summary Of Significant Accounting Practices Policies	'
Loss per Share	'
	Loss per Share
	Basic earnings (loss) per share is computed by dividing the net income (loss) applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed by dividing the net income (loss) applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. For the years ended December 31, 2013 and 2012, the calculations of basic and diluted loss per share are the same because inclusion of potential dilutive securities in the computation would have an anti-dilutive effect due to the net losses.
	The potentially dilutive securities at December 31, 2013 consist of options to acquire 278,750 shares of the Company’s common stock and warrants to acquire 12,373,156 shares of common stock.
Fair Value Measurements	'
	Fair Value Measurements
	The Company uses various inputs in determining the fair value of certain assets and liabilities and measures these on a recurring basis. Financial assets and liabilities recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. Authoritative guidance provided by the Financial Accounting Standards Board (the “FASB”) defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets and liabilities:
	Level 1—Quoted prices in active markets for identical assets or liabilities.
	Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.
	Level 3—Unobservable inputs based on the Company's assumptions.
Derivative financial instruments	'
	Derivative Financial Instruments
	The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives.  The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.  Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date.
	For stock-based derivative financial instruments, the Company used probability weighted average Black-Scholes-Merton models to value the derivative instruments at inception and on subsequent valuation dates through March 31, 2013.  At December 31, 2012, the Company used the assistance of a valuation specialist to determine the fair value of the derivative liability. On May 22, 2013, upon the completed restructuring of the Company’s debt and equity securities (“financial instruments”) (see Note 5), all financial instruments held at that time that were accounted for as a derivative liability were converted into shares of the Company’s common stock.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Stock-Based Compensation	'
	Stock-Based Compensation
	The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for stock option and warrant grants issued and vesting to employees based on the authoritative guidance provided by the Financial Accounting Standards Board where the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board where the value of the stock compensation is determined based upon the measurement date as at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.
	The fair value of the Company's common stock option grants are estimated using a Black-Scholes option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	The FASB has issued Accounting Standards Update (ASU) No. 2013-04, Liabilities (Topic 405), “Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date.” ASU 2013-04 provides guidance for the recognition, measurement, and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation within the scope of this ASU is fixed at the reporting date, except for obligations addressed within existing guidance in U.S. GAAP. The guidance requires an entity to measure those obligations as the sum of the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors and any additional amount the reporting entity expects to pay on behalf of its co-obligors. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company does not expect the adoption of this guidance to have a material impact on the Company’s financial statements.
	In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of Unrecognized Tax Benefit When a Net Operating Loss Carryforward, A Similar Tax Loss, or a Tax Credit Carryforward Exists (A Consensus the FASB Emerging Issues Task Force). ASU 2013-11 provides guidance on financial statement presentation of unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The FASB’s objective in issuing this ASU is to eliminate diversity in practice resulting from a lack of guidance on this topic in current U.S. GAAP. This ASU applies to all entities with unrecognized tax benefits that also have tax loss or tax credit carryforwards in the same tax jurisdiction as of the reporting date. This amendment is effective for public entities for fiscal years beginning after December 15, 2013 and interim periods within those years. The company does not expect the adoption of this standard to have a material impact on the Company’s financial position and results of operations.
	Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC did not or are not believed by management to have a material impact on the Company's present or future financial statements.

8_STOCK_OPTIONS_AND_WARRANT_Ta

8. STOCK OPTIONS AND WARRANT (Tables)	12 Months Ended
	Dec. 31, 2013
Stock Options And Warrant Tables	'
Stock Options	'
								Weighted
					Weighted			Average
		Shares			Average			Remaining	Aggregate
		Under			Exercise			Contractual	Intrinsic
		Option			Price			Life	Value
	Outstanding at December 31, 2011		92,750		$	109		8.5 years	$	1,114,063
	Granted		3,000			104
	Exercised
	Expired/Forfeited		(2,000	)		92
	Outstanding at December 31, 2012		93,750			107		7.7 years	$	217,063
	Granted		225,000			5.65
	Exercised
	Expired/Forfeited		(40,000	)		125
	Outstanding at December 31, 2013		278,750		$	23.1		9.1 years	$	1,176,063
	Exercisable at December 31, 2013		81,687		$	45.1		7.8 years	$	344,642
Black-Scholes option pricing model	'
		Year ended
		December 31,
		2013			2012
	Expected volatility		236	%		208	%
	Expected dividends		0			0
	Expected average term (in years)		5.38			4.25
	Risk free rate - average		2.67	%		1.78	%
	Forfeiture rate		0			0
Warrants	'
								Weighted
					Weighted			Average
		Shares			Average			Remaining	Aggregate
		Under			Exercise			Contractual	Intrinsic
		Warrants			Price			Life	Value
	Outstanding at December 31, 2011		96,800		$	122		4.5 years	$	-
	Issued		11,934			125
	Exercised
	Expired		-
	Outstanding at December 31, 2012		108,734		$	123		3.5 years	$	-
	Issued		12,387,156			2.5
	Exercised		-122,734
	Expired		-
	Outstanding and exercisable at December 31, 2013		12,373,156		$	2.51		4.11 years	$	31,056,390

9_INCOME_TAXES_Tables

9. INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Significant components of the Company's deferred income tax assets	'
		December 31,			December 31,
		2013			2012
	Deferred income tax asset:
	Net operating loss carry forward		3,679,022			6,957,129
	Valuation allowance		(3,679,022	)		(6,957,129	)
	Net deferred income tax asset	$	—		$	—
Reconciliation of the effective income tax rate	'
		Year Ended
		December 31,
		2013			2012
	Federal Statutory tax rate		(34	) %		(34	) %
	State tax, net of federal benefit		(5	) %		(5	) %
			(39	) %		(39	) %
	Valuation allowance		39	%		39	%
	Effective tax rate		-	%		-	%

1_GENERAL_ORGANIZATION_AND_BUS1

1. GENERAL ORGANIZATION AND BUSINESS (Details Narrative) (USD $)	12 Months Ended					15 Months Ended	72 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2013	Dec. 16, 2007	Sep. 16, 2007
General Organization And Business Details Narrative	'	'	'	'	'	'	'	'	'
Net loss	$25,381,363	$3,307,619	$25,694,100	$1,607,988	$15,772	$58,716	$56,065,558	'	'
Net Cash Used In Operating Activities	-3,662,192	-2,241,467	'	'	'	'	-12,785,526	'	'
Stockholders' equity	17,603,717	-11,319,476	-12,780,918	638,085	-13,488	2,284	17,603,717	'	8,000
Net proceeds of the Private Placement	21,985,000	'	'	'	'	'	'	'	'
Working capital	17,576,000	'	'	'	'	'	17,576,000	'	'
Cash or cash equivalents	$19,672,177	$0	$510,217	'	'	'	$19,672,177	$0	'

2_SUMMARY_OF_SIGNIFICANT_ACCOU2

2. SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Details Narrative)	12 Months Ended
	Dec. 31, 2013
Option [Member]	'
Potentially dilutive securities	278,750
Warrant [Member]	'
Potentially dilutive securities	12,373,156

8_STOCK_OPTIONS_AND_WARRANTS_D

8. STOCK OPTIONS AND WARRANTS (Details) (Option [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Option [Member]	'	'
Shares Under Option	'	'
Outstanding beginning balance	93,750	92,750
Granted	225,000	3,000
Exercised	0	0
Expired/Forfeited	-40,000	-2,000
Outstanding ending balance	278,750	93,750
Exercisable ending balance	81,687	'
Weighted Average Exercise Price	'	'
Outstanding beginning balance	$107	$109
Granted	$5.65	$104
Exercised	'	'
Expired	$125	$92
Outstanding ending balance	$23.10	$107
Exercisable ending balance	$45.10	'
Outstanding beginning balance	'7 years 8 months 12 days	'8 years 6 months
Outstanding ending balance	'9 years 1 month 6 days	'7 years 8 months 12 days
Exercisable ending balance	'7 years 9 months 18 days	'
Aggregate Intrinsic Value	'	'
Outstanding beginning balance	$217,063	$1,114,063
Outstanding ending balance	1,176,063	217,063
Exercisable ending balance	$344,642	'

8_STOCK_OPTIONS_AND_WARRANT_De

8. STOCK OPTIONS AND WARRANT (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Stock Options And Warrant Tables	'	'
Expected volatility	236.00%	208.00%
Expected dividends	$0	$0
Expected average term (in years)	'5 years 4 months 17 days	'4 years 3 months
Risk free rate - average	2.67%	1.78%
Forfeiture rate	0.00%	0.00%

8_STOCK_OPTIONS_AND_WARRANTS_D1

8. STOCK OPTIONS AND WARRANTS (Details 2) (Warrant [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Warrant [Member]	'	'
Shares Under Warrants	'	'
Outstanding beginning balance	108,734	96,800
Issued	12,387,156	11,934
Exercised	-122,734	'
Expired	'	'
Outstanding ending balance	12,373,156	108,734
Weighted Average Exercise Price	'	'
Outstanding beginning balance	$123	$122
Issued	$2.50	$125
Expired	'	'
Outstanding ending balance	$2.51	$123
Outstanding beginning balance	'3 years 6 months	'4 years 6 months
Outstanding ending balance	'4 years 1 month 10 days	'3 years 6 months
Aggregate Intrinsic Value	'	'
Outstanding beginning balance	$0	$0
Outstanding ending balance	$31,056,390	$0

9_INCOME_TAXES_Details

9. INCOME TAXES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred income tax asset:	'	'
Net operating loss carry forward	$3,679,022	$6,957,129
Valuation allowance	-3,679,022	-6,957,129
Net deferred income tax asset	$0	$0

9_INCOME_TAXES_Details_1

9. INCOME TAXES (Details 1)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Federal Statutory tax rate	-34.00%	-34.00%
State tax, net of federal benefit	-5.00%	-5.00%
Total	-39.00%	-39.00%
Valuation allowance	39.00%	39.00%
Effective tax rate	0.00%	0.00%

11_RELATED_PARTY_TRANSACTIONS_

11. RELATED PARTY TRANSACTIONS (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Related Party Transactions Details Narrative	'	'
Unpaid salaries due officers and fees to board members	$338,731	$395,081
Consulting expenses from related party - Emmes	$22,412	'